Polymyositis, dermatomyositis, and inclusion body myositis

REFERENCES
1. Soni MK, Cella DF, Masters GA, et al. The validity and clinical utility
of symptom monitoring in advanced lung cancer: a literature review.
Clin Lung Cancer 2002;4:1–2.
2. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early lung cancer
action project: overall design and findings from baseline screening.
Lancet 1999;354:99–105.
3. Mountain C. Clinical biology of small cell carcinoma: relationship to
surgical therapy. Semin Oncol 1978;5:272–279.
4. Feinstein MB, Stover D. Clinical features of lung cancer. In: Ginsburg
RJ, ed. The American Cancer Society Atlas of Clinical Oncology .
Hamilton, Canada: BC Decker, Inc., 2002:43–56.
5. Beckles MA, Spiro SG, Colice GL, et al. Initial evaluation of the patient
with lung cancer. Chest 2003;123:S97–S104.
6. Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of
1539 population based lung cancer patients by cell type and stage in
New Hampshire and Vermont. Cancer 1985;56:2107–2111.
7. Abrams J, Doyle LA, Aisner J. Staging, prognostic factors, and special
considerations in small cell lung cancer. Semin Oncol 1988;15:261–277.
8. Buccheri G, Ferrigno D. Symptomatic pattern, alarm symptoms and
diagnostic delay in a cohort of 1277 consecutive lung cancer patients.
Lung Cancer 2003;41:S196 (abst P-411).
9. Osterlind K, Ihde DC, Ettinger DS, et al. Staging and prognostic
factors in small cell carcinoma of the lung. Cancer Treat Rep 1983;
67:3–9.
10. Warren S. The immediate causes of death in cancer. Am J Med Sci
1932;184:610–615.
11. Nathanson L, Puccio M. The cancer cachexia syndrome. Semin Oncol
1997;24:277–287.
12. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome.
J Clin Oncol 1994;12:213–225.
13. Okuyama T, Tanaka K, Akechi G, et al. Fatigue in ambulatory patients
with advanced lung cancer: prevalence, correlated factors, and screening.
J Pain Symptom Manage 2001;22:554–564.
14. Stommel M, Given BA, Given CW. Depression and functional status
as predictors of death among cancer patients. Cancer 2002;94:
2719–2727.
15. Naughton MJ, Herndon JE, Shumaker SA, et al. The health-related
quality of life and survival of small-cell lung cancer patients: results
of a companion study to CALGB 9033. Qual Life Res 2002;11:
235–248.
16. Chang CH, Cella D, Masters GA, et al. Real-time clinical application
of quality of life assessment in advanced lung cancer. Clin Lung Cancer
2002;4:104–109.
17. Grippi MA. Clinical aspects of lung cancer. Semin Roentgen 1990;25:
12–24.
18. Filderman AE, Shaw C, Matthay RA. Lung cancer. Part 1: etiology, pathology,
natural history, manifestions, and diagnostic techniques. Invest
Radiol 1986;21:80–90.
19. Patel AM, Peters SG. Clinical manifestations of lung cancer. Mayo Clin
Proc 1993;68:273–277.
20. Hirshberg B, Biran I, Glazer, M, et al. Hemoptysis: etiology evaluations
and outcome in a tertiary referral hospital. Chest 1997;112:440–444.
21. O’Neil KM, Lazarus AA. Hemoptysis: indications for bronchoscopy.
Arch Intern Med 1991;151:171–174.
22. Poe RH, Israel RH, Marin MA, et al. Utility of fiberoptic bronchoscopy
in patients with hemoptysis and a non-localizing chest roentgenogram.
Chest 1988;93:70–75.
23. Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest 1974;
65:299–306.
24. Farber SM, Mandel W, Spain DM. Diagnosis and Treatment of Tumors
of the Chest. New York: Grune and Stratton, 1960.
25. Christie NA, Buenaventura PO, Fernando HC, et al. Results of expandable
metal stents for malignant esophageal obstruction in 100 patients:
short-term and long-term follow-up. Ann Thorac Surg 2001;71:
1797–801.
26. Fincher RE. Superior vena cava syndrome: Experience in a teaching
hospital. South Med J 1987;80:1243–1245.
27. Urban T, Lebeau B, Chastang C, et al. Superior vena cava syndrome in
small cell lung cancer. Arch Intern Med 1993;153:384–387.
28. Kraus DH, Ali MK, Ginsberg RJ, et al. Vocal cord medialization for
unilateral paralysis associated with intrathoracic malignancies. J Thorac
Cardiovasc Surg 1996;111:334–339.
29. Torre M, Amari D, Barbieri B, et al. Emergency laser vaporization and
helium oxygen administered for acute malignant tracheobronchial obstruction.
Am J Emerg Med 1989;7:294–296.
30. Park JS, Rentschler R, Wilbur D. Surgical management of pericardial
effusion in patients with malignancies. Comparison of subxiphoid window
versus pericardiectomy. Cancer 1991;67:76–80.
31. Lynch TJ. Management of malignant pleural effusions. Chest
1993;103(Suppl 4):S385–S389.
32. Chernow B, Sahn SA. Carcinomatous involvement of the pleura. Am J
Med 1977;63:695–702.
33. Johnston WW. The malignant pleural effusion. Cancer 1985;56:
905–909.
34. Livingston RB, McCracken JD, Trauth CJ, et al. Isolated pleural
effusion in small cell lung carcinoma: Favorable prognosis. Chest
1982;81:208–211.
35. Light RW. Pleural effusion. N Engl J Med 2002;346:1971–1977.
36. Johnson DH, Hainsworth JD, Greco FA. Pancoast’s syndrome and
small cell lung cancer. Chest 1982;82:602–606.
37. Paulson D. Carcinomas in the superior pulmonary sulcus. J Thorac
Cardiovasc Surg 1975;70:1095–1094.
38. Luketich JD, Ginsberg RJ. Diagnosis and staging of lung cancer. In:
Johnson BE, Johnson DH, eds. Lung Cancer. New York: Wiley-Liss,
Inc., 1995:161–173.
39. Silvestri GA, Littenberg B, Colice GL. The clinical evaluation for detecting
metastatic lung caner: a meta-analysis. Am J Respir Crit Care
Med 1995;152:225–230.
40. Tritz DB, Doll DC, Ringenberg S, et al. Bone marrow involvement in
small cell lung cancer. Cancer 1989;63:763–766.
41. Kut V, Spies W, Spies S, et al. FDG-positron emission tomography
in the staging and monitoring of small cell lung cancer. Lung Cancer
2003;41:S200 (abstr. P-429).
42. Pederson AG. Diagnosis of CNS metastases from SCLC. In: Hansen
HH, ed. Lung Cancer: Basic and Clinical Aspects. Boston: Martinus
Nijhoff, 1986:153–182.
43. Hooper RG, Tenholder MF, Underwood GH, et al. Computed tomographic
scanning of the brain in initial staging of bronchogenic carcinoma.
Chest 1984;85:774–776.
44. Postmus PE. Brain Metastases from small cell lung cancer: chemotherapy,
radiotherapy, or both? Semin Radiat Oncol 1995;5:69–73.
45. Grossman SA, Krabak MJ. Leptomeningeal carcinomatosis. Cancer
Treat Rev 1999;25:103–119.
46. Rosen L, Gordon D, Tchekmedyian V, et al. Zoledronic acid (Zol)
significantly reduces skeletal-related events (SREs) in patients with
bone metastases from solid tumors. Proc Am Soc Clin Oncol 2002;21:
No.1179 (abstr).
47. Silvestri GA, Lenz JE, Harper SN, et al. The relationship of clinical
findings to CT scan evidence of adrenal gland metastases in the staging
of bronchogenic carcinoma. Chest 1992;102:1748–1751.
48. Potti A, Schell DA. Unusual presentations of thoracic tumors: case 1.
Acute adrenal insufficiency due to metastatic lung cancer. J Clin Oncol
2001;19:3780–3782.
49. Bhattacharya R, Rao S, Kowdley KV. Liver involvement in patients
with solid tumors of nonhepatic origin. Clin Liver Dis 2002;6:
1033–1043.
50. Richardson GE, Johnson BE. Paraneoplastic syndromes in lung cancer.
Curr Opin Oncol 1992;4:323–333.
51. Greenberg E, Divertie MB, Woolner LB. A review of unusual systemic
manifestations associated with cancer. Am J Med 1964;36:106–120.
52. Heber D, Tchekmedyian NS. Mechanism of cancer cachexia. Contemp
Oncol 1995;6–10.
53. Wilding JD. Neuropeptides and appetite control. Diabet Med
2002;19:619–627.
54. Lanstein HN, Norton JA. Mechanism of cancer cachexia. Hematol
Oncol Clin North Am 1991;5:103–123.
55. DeWys WD, Begg C, Lavin PT, et al. Prognostic effect of weight
loss prior to chemotherapy in cancer patients. Am J Med 1980;69:
491–497.
56. Pearse AG. Common cytochemical and ultrastructural characteristics
of cells producing polypeptide hormones and their relevance to thyroid
and ultimobronchial C cells and calcitonin. Proc R Soc Lond B Biol Sci
1968;170:71–80.
57. Yellin A, Benfield JR. The pulmonary Kulchitsky cell (neuroendocrine)
cancers: from carcinoid to small cell carcinomas. Curr Probl Cancer
1985;9:1–38.
58. Odell WD. Endocrine/metabolic syndromes of cancer. Semin Oncol
1997;24:299–317.
59. Mendelsohn G, Baylin SB. Ectopic hormone production—biological
and clinical implications. Prog Clin Biol Res 1984;142:291–316.
60. Hansen M, Bork E. Peptide hormones in patients with lung cancer.
Recent Results Cancer Res 1985;99:180–186.
61. Shepherd FA, Laskey J, Evans WK, et al. Cushing’s syndrome associated
with ectopic corticotropin production and small cell lung cancer.
J Clin Oncol 1992;10:21–27.
62. Nieman LK, Chrousos GP, Oldfield EH, et al. Diagnosis and management
of ACTH-dependent Cushing’s syndrome: comparison and the
features in ectopic and pituitary ACTH production. Clin Endocrinol
1986;24:699–713.
63. Gilby ED, Rees LH, Bondy PK. Ectopic Hormones as Markers of Response
to Therapy in Cancer. Advances in Tumour Prevention, Detection and
Characterization, Vol. 3. Proceedings of the 6th International Symposium
on Biological Characterization of Human Tumours. New York: Elsevier,
1976:132.
64. Vorherr H, Massry SG, Utiger RD, et al. Anti-diuretic principle in
malignant tumor extracts from patients with inappropriate ADH syndrome.
J Clin Endocrinol Metab 1968;28:162–168.
65. Odell WD, Wolfesen A, Yoshimoto Y, et al. Ectopic peptide synthesis:
a universal concomitant of neoplasia. Trans Assoc Am Physicians 1977;
90:204–227.
66. North WG, LaRochelle FT Jr, Melton J, et al. Human neurophysins
(HNPs) as potential tumor markers for small-cell carcinomas (SCC).
Clin Res 1978;26:536A (abstr).
67. List AF, Hainsworth JD, Davis BW, et al. The syndrome of inappropriate
secretion of antidiuretic hormone (SIADH) in small cell lung
cancer. J Clin Oncol 1986;4:1191–1198.
68. van Oosterhort AG, van de Pol M, ten Velde GP, et al. Neurologic disorders
in 203 consecutive patients with small cell lung cancer. Cancer
1996;77:1434–1441.
69. Dalmau JO, Posner JB. Paraneoplastic syndromes affecting the nervous
system. Semin Oncol 1997;24:318–328.
70. Grisold W, Drlicek M, Liszka-Setinek U, et al. Anti-tumour therapy
in paraneoplastic neurologic disease. Clin Neurol Neurosurg 1995;97:
112–116.
71. Graus F, Delattre J. Immune modulation of paraneoplastic disorders.
Clin Neurol Neurosurg 1995;97:112–116.
72. Erlington GM, Murray NM, Spiro SG, et al. Neurological paraneoplastic
disorders in patients with small cell lung cancer: a prospective survey
of 150 patients. J Neurol Neurosurg Psychiatr 1991;54:764–767.
73. Latov N, Chaudhry V, Koski CL, et al. Use of intravenous gamma
globulins in neuroimmunologic diseases. J Allergy Clin Immunol
2001;108(4 Suppl):S126–S132.
74. Maddison P, Newsom-Davis J, Mills KR, et al. Favourable prognosis in
Lambert-Eaton myasthenic syndrome and small cell lung carcinoma.
Lancet 1999;353:117–118.
75. Lieberman FS, Schold SC. Distant effects of cancer on the nervous
system. Oncology 2002;16:1539–1548.
76. Mason WP, Graus F, Valideoriola F, et al. Paraneoplastic cerebellar degeneration
(PCD) in small-cell lung cancer: impact of anti-Hu antibody
(HuAb) on clinical presentation and survival. Neurology 1996;46:
A127–A128 (abstr).
77. Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis:
neurological symptoms, immunological findings, and tumour
association in 50 patients. Brain 2000;123:1481–1494.
78. Dalmau J, Grau F, Rosenblum MK, et al. Anti-Hu-associate paraneoplastic
encephalomyelitis/sensory neuropathy. A clinical study of 71
patients. Medicine 1992;71:59–72.
79. Meinck HM, Thompson PD. Stiff man syndrome and related conditions.
Mov Disord 1992;110:853–866.
80. Keltner JL, Thirkill CE, Tyler NK, et al. Management and monitoring
of cancer associated retinopathy. Arch Ophthalmol 1992;110:48–53.
81. Luiz JE, Lee AG, Keltner JL, et al. Paraneoplastic optic neuropathy
and autoantibody production in small cell carcinoma of the lung.
J Neuroophthalmol 1998;18:178–181.
82. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin
Oncol 1994;21(Suppl 3):3–8.
83. Richard MS. Metastatic cancer of unknown primary site. In: Fauci AS,
Braunwald E, Isselbacher KJ, et al., eds. Harrison’s Principles of Internal
Medicine . 14th ed. New York: McGraw-Hill, 1998:614–622.
84. Gastl G, Plante M, Finstead CI, et al. High IL-6 levels in ascetic fluid
correlate with reactive thrombocytosis with epithelial ovarian cancer. Br
J Hematol 1993;83:433–441.
85. Estrov Z, Talpaz M, Maligit G, et al. Elevated plasma thrombo poietin
activity in patients with cancer related thrombocytosis. Am J Med
1995;98:551–558.
86. Prandoni P, Lensing AW, Butler HR, et al. Deep-vein thrombosis
and the incidence of subsequent symptomatic cancer. N Engl J Med
1992;327:1128–1133.
87. Green KB, Silverstein RL. Hypercoagulability in cancer. Hematol Oncol
Clin North Am 1996;10:506–507.
88. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with
warfarin against recurrent venous thromboembolism. N Engl J Med
2000;342:1953–1958.
89. Schneerson JM. Digital clubbing and hypertrophic osteoarthropathy:
The underlying mechanisms. Br J Dis Chest 1981;75:113–131.
90. Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer.
Chest 1998;114:1535–1537.
91. Segal AM, Mackenzie AH. Hypertrophic osteoarthropathy: a 10 year
retrospective analysis. Semin Arthrit Rheum 1982;12:220–232.
92. Sigurgeirsson B, Lindelof B, Edhag O, et al. Risk of cancer in patients
with dermatomyositis and polymyositis: A population based study.
N Engl J Med 1992;326:363–367.
93. Cohen PR, Razelle R. Mucocutaneous paraneoplastic syndromes.
Semin Oncol 1997;41:334–359.
94. Dalakas MC. Polymyositis, dermatomyositis, and inclusion body
myositis. In: Braunwald E, Fauci A, Kasper DL, et al., eds. Principles
of Internal Medicine, 15th ed. New York: McGraw-Hill, 2001:
2524–2529.
95. Cohen PR, Grossman ME, Almeida L, et al. Tripe palms and malignancy.
J Clin Oncol 1989;7:669–678.
96. Lee JC, Yamauchi H, Hopper J. The association of cancer and the
nephritic syndrome. Ann Int Med 1966;64:41–51.